Articles by Neil Bhowmick, PhD
Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification
ByBethany Smith, PhD,Sungjin Kim, MS ,Mourad Tighiouart, PhD,Edwin M. Posadas, MD,Leland Chung, PhD,Robert A. Figlin, MD,Neil Bhowmick, PhD,Jun Gong, MD Published: | Updated: This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.
Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics
ByJun Gong, MD,Edwin M. Posadas, MD,Neil Bhowmick, PhD,Hyung L. Kim, MD,Timothy J. Daskivich, MD,Amit Gupta, MD,Howard M. Sandler, MD,Mitchell Kamrava, MD,Zachary S. Zumsteg, MD,Stephen J. Freedland, MD,Robert A. Figlin, MD Published: | Updated: Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.
